4-(2-Bromoethyl)benzenesulfonamide → 1-[1-(4-Sulfamoylphenethyl)piperidin-4-yl]indoline
Reaction equation
[NH:1]1[CH2:6][CH2:5][CH:4]([N:7]2[C:15]3[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=3)[CH2:9][CH2:8]2)[CH2:3][CH2:2]1.[S:16]([C:20]1[CH:28]=[CH:27][C:23]([CH2:24][CH2:25]Br)=[CH:22][CH:21]=1)(=[O:19])(=[O:18])[NH2:17]>>[S:16]([C:20]1[CH:28]=[CH:27][C:23]([CH2:24][CH2:25][N:1]2[CH2:6][CH2:5][CH:4]([N:7]3[C:15]4[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=4)[CH2:9][CH2:8]3)[CH2:3][CH2:2]2)=[CH:22][CH:21]=1)(=[O:18])(=[O:19])[NH2:17]Participants
3
Procedure
1-(Piperidin-4-yl)indoline (300 mg) and 4-sulfamoylphenethyl bromide (400 mg) were treated as in Example 2 to give the title compound (60 mg) as a pale yellow powder (yield: 10%).
Sources & evidence
- ORD record
- ord-58b15d9f5d06430c8c06f339cd5d714b
- Source dataset
- uspto-grants-2006_07
- Patent number
- US07071201B2
Reaction notes
Loading…